Luciana Mirotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luciana Mirotti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
M. Russo
Departamento de Imunologia Instituto de Ciências Biomédicas Universidade de São Paulo São Paulo Brasil
2 shared publicationsD. Mucida
La Jolla Institute for Allergy and Immunology, United States
1 shared publication- Eliane Gomes
Institute of Biomedical Sciences, Department of Immunology, University of Sao Paulo, Sao Paulo 05508-000, Brazil
1 shared publication - Esther Borges Florsheim
Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ
1 shared publication F. Spinozzi
Laboratory of Experimental Immunology and Allergy Department of Clinical and Experimental Medicine University of Perugia Perugia Italy
1 shared publicationF.A. Costa-Pinto
University of Sao Paulo, Sao Paulo, SP 05508-270, Brazil
1 shared publication
Latest Publications
- Open Access
Dendritic Cells Expressing MyD88 Molecule Are Necessary and Sufficient for CpG-Mediated Inhibition of IgE Production In Vivo
Elevated levels of immunoglobulin E (IgE) are associated with allergies and other immunological disorders. Sensitization with alum adjuvant favours IgE production while CpG-ODN adjuvant, a synthetic toll-like receptor 9 (TLR9) agonist, inhibits it. The cellular mechanisms underlying in vivo TLR regulation of immunoglobulin production, specially IgE, are still controversial. Specifically, TLR-mediated IgE regulation in vivo is not yet known. In this study we showed that augmented levels of IgE induced by sensitizations to OVA with or without alum adjuvant or with OVA-pulsed dendritic cells (DCs) were inhibited by co-administration of CpG. Notably, CpG-mediated suppression of IgE production required MyD88-expression on DCs but not on B-cells. This finding contrasts with previous in vitro studies reporting regulation of IgE by a direct action of CpG on B cells via MyD88 pathway. In addition, we showed that CpG also inhibited IgE production in a MyD88-dependent manner when sensitization was performed with OVA-pulsed DCs. Finally, CpG signalling through MyD88 pathway was also necessary and sufficient to prevent anaphylactic antibody production involved in active cutaneous anaphylaxis.
Open AccessDendritic Cells Expressing MyD88 Molecule Are Necessary and Sufficient for CpG-Mediated Inhibition of IgE Production In Vivo
Elevated levels of immunoglobulin E (IgE) are associated with allergies and other immunological disorders. Sensitization with alum adjuvant favours IgE production while CpG-ODN adjuvant, a synthetic toll-like receptor 9 (TLR9) agonist, inhibits it. The cellular mechanisms underlying in vivo TLR regulation of immunoglobulin production, specially IgE, are still controversial. Specifically, TLR-mediated IgE regulation in vivo is not yet known. In this study we showed that augmented levels of IgE induced by sensitizations to OVA with or without alum adjuvant or with OVA-pulsed dendritic cells (DCs) were inhibited by co-administration of CpG. Notably, CpG-mediated suppression of IgE production required MyD88-expression on DCs but not on B-cells. This finding contrasts with previous in vitro studies reporting regulation of IgE by a direct action of CpG on B cells via MyD88 pathway. In addition, we showed that CpG also inhibited IgE production in a MyD88-dependent manner when sensitization was performed with OVA-pulsed DCs. Finally, CpG signalling through MyD88 pathway was also necessary and sufficient to prevent anaphylactic antibody production involved in active cutaneous anaphylaxis.
Lipids are required for the development of Brazil nut allergy: the role of mouse and human iNKT cells
Background: Lipids are required for mice sensitization to Ber e 1, Brazil nut major allergen. Here, we characterized different lipid fractions extracted from Brazil nuts and the lipid‐binding ability of Ber e 1. Further, we determined their in vivo ability to induce Ber‐specific anaphylactic antibodies and the role of invariant natural killer T (iNKT) cells in this process.Methods: Wild‐type (WT) and iNKT cell‐deficient mice were sensitized with Ber e 1 and specific lipid fractions, and anaphylactic antibodies were measured by enzyme‐linked immunosorbent assay (ELISA) and passive cutaneous anaphylaxis (PCA). The lipid‐binding characteristic of Ber e 1 (Ber) was established by using fluorescent probes and 15N‐labeled NMR. In vitro production of IL‐4 was determined in Ber/lipid C‐stimulated mouse iNKT cells and human T‐cell lines containing NKTs primed with CD1d+C1R transfectants by flow cytometry and ELISA, respectively.Results: Only one specific lipid fraction (lipid C), containing neutral and common phospholipids, induced Ber anaphylactic antibodies in mice. Ber e 1 has a lipid‐binding site, and our results indicated an interaction between Ber e 1 and lipid C. iNKT‐deficient mice produced lower levels of anaphylactic antibodies than WT mice. In vitro, Ber/lipid C‐stimulated murine iNKT cells produced IL‐4 but not IFN‐gamma. Human T‐cell lines derived from nut‐allergic patients produced IL‐4 to Ber/lipid C in a CD1d− and dose‐dependent manner.Conclusion: Lipid fraction C from Brazil nut presents an essential adjuvant activity to Ber e 1 sensitization, and iNKT cells play a critical role in the development of Brazil nut‐allergic response.
Lipids are required for the development of Brazil nut allergy: the role of mouse and human iNKT cells
Background: Lipids are required for mice sensitization to Ber e 1, Brazil nut major allergen. Here, we characterized different lipid fractions extracted from Brazil nuts and the lipid‐binding ability of Ber e 1. Further, we determined their in vivo ability to induce Ber‐specific anaphylactic antibodies and the role of invariant natural killer T (iNKT) cells in this process.Methods: Wild‐type (WT) and iNKT cell‐deficient mice were sensitized with Ber e 1 and specific lipid fractions, and anaphylactic antibodies were measured by enzyme‐linked immunosorbent assay (ELISA) and passive cutaneous anaphylaxis (PCA). The lipid‐binding characteristic of Ber e 1 (Ber) was established by using fluorescent probes and 15N‐labeled NMR. In vitro production of IL‐4 was determined in Ber/lipid C‐stimulated mouse iNKT cells and human T‐cell lines containing NKTs primed with CD1d+C1R transfectants by flow cytometry and ELISA, respectively.Results: Only one specific lipid fraction (lipid C), containing neutral and common phospholipids, induced Ber anaphylactic antibodies in mice. Ber e 1 has a lipid‐binding site, and our results indicated an interaction between Ber e 1 and lipid C. iNKT‐deficient mice produced lower levels of anaphylactic antibodies than WT mice. In vitro, Ber/lipid C‐stimulated murine iNKT cells produced IL‐4 but not IFN‐gamma. Human T‐cell lines derived from nut‐allergic patients produced IL‐4 to Ber/lipid C in a CD1d− and dose‐dependent manner.Conclusion: Lipid fraction C from Brazil nut presents an essential adjuvant activity to Ber e 1 sensitization, and iNKT cells play a critical role in the development of Brazil nut‐allergic response.
- 31 August 2010
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 24, S33
A critical balance between allergen-specific IGE levels and taste preference during food aversion
- 31 August 2010
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 24, S33
A critical balance between allergen-specific IGE levels and taste preference during food aversion